Skip to content
Acquisitions Help Jazz Build Toward Commercial Crescendo episode artwork

Feb 12, 2021 21 min

Acquisitions Help Jazz Build Toward Commercial Crescendo

from RARECast

Jazz Pharmaceuticals has been successful at building and commercializing a growing pipeline of therapies to treat rare neurologic conditions and hematologic cancers. Central to its strategy has been the use of acquisitions to build its pipeline. In fact, we should note that since recording this podcast, the company continued that approach with news that it would acquire GW Pharmaceuticals for $7.2 billion to expand its neuroscience portfolio. We spoke to Robert Iannone, executive vice president of research and development and chief medical officer of Jazz about the company’s neuroscience pipeline, its growing family of commercial products, and how its preparing to maintain its leadership in the treatment of the rare sleep disorder narcolepsy as new competitors move toward market.

Episode details come from the podcast's RSS feed.

Embed this episode

Robert Iannone, executive vice president of research and development and chief medical officer of Jazz Pharmaceuticals, discusses the company’s neuroscience pipeline, its growing family of commercial products, and how its preparing to maintain its leadership in the treatment of the rare sleep disorder narcolepsy as new competitors move toward market.

Ready to play

Acquisitions Help Jazz Build Toward Commercial Crescendo

0:00 21:53

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of RARECast?

This episode is 21 minutes long.

When was this RARECast episode published?

This episode was published on February 12, 2021.

Can I download this RARECast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.